NuCana (NCNA) Accounts Payables (2016 - 2025)
NuCana's (NCNA) quarterly Accounts Payables came in at $694346.8 in Q4 2025, down 80.0% year-on-year from $3.5 million in Q4 2024, and down 69.04% quarter-over-quarter from $2.2 million in Q3 2025.
NuCana (NCNA) Accounts Payables (2016 - 2025) Analysis & Trends
NuCana has disclosed Accounts Payables across 10 years of filings, most recently posting $694346.8 for Q4 2025.
- Accounts Payables for Q4 2025 came in at $694346.8, down 80.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $694346.8 (down 80.0% YoY), and the FY2025 annual result was $688262.4, down 80.09% from the prior year.
- Accounts Payables came in at $694346.8 for Q4 2025 at NuCana, down from $2.2 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $7.9 million in Q3 2024 to a low of $694346.8 in Q4 2025.
- The 5-year median for Accounts Payables is $4.5 million (2021), against an average of $4.5 million.
- Across the five-year window, Accounts Payables jumped 128.5% in 2022 and slumped 81.0% in 2025, its largest moves.
- NuCana's Accounts Payables stood at $2.5 million in 2021, then surged by 128.5% to $5.6 million in 2022, then dropped by 25.64% to $4.2 million in 2023, then fell by 17.12% to $3.5 million in 2024, then slumped by 80.0% to $694346.8 in 2025.
- The last three Accounts Payables figures came in at $694346.8 (Q4 2025), $2.2 million (Q3 2025), and $1.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 8.64 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 34.55 Mn |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | 694,346.76 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 694,346.76 |
| Sep 30, 2025 | 2.24 Mn |
| Jun 30, 2025 | 1.46 Mn |
| Mar 31, 2025 | 3.03 Mn |
| Dec 31, 2024 | 3.47 Mn |
| Sep 30, 2024 | 7.85 Mn |
| Jun 30, 2024 | 7.71 Mn |
| Mar 31, 2024 | 7.31 Mn |
| Dec 31, 2023 | 4.19 Mn |
| Sep 30, 2023 | 6.55 Mn |
| Jun 30, 2023 | 5.86 Mn |
| Mar 31, 2023 | 6.92 Mn |
| Dec 31, 2022 | 5.63 Mn |
| Sep 30, 2022 | 6.62 Mn |
| Jun 30, 2022 | 2.70 Mn |
| Mar 31, 2022 | 3.62 Mn |
| Dec 31, 2021 | 2.47 Mn |
| Sep 30, 2021 | 5.36 Mn |
| Jun 30, 2021 | 2.37 Mn |
| Mar 31, 2021 | 4.88 Mn |